CNS Response Announces Fiscal Third Quarter 20...(Net loss for the three-month period ende...)

Date:8/19/2007

Net loss for the three-month period ended June 30, 2007 was $(502,700), or $(0.02) per diluted share, compared to a net loss of $(510,000), or $(0.25) per diluted share, during the same period last year. The net loss for the three month period ended June 30, 2007 consists of an operating loss of $(557,900) offset by other income of $55,200. The net loss for the three month period ended June 30, 2006 consists of an operating loss of $(363,900) and interest expense of $(146,100). The increase in operating loss is due primarily to the costs incurred in connection with the ongoing multi-site clinical study.

About CNS Response

CNS Response is a life sciences company focused on the commercialization of the first patented system that guides psychiatrists in pharmacotherapy for patients with certain behavioral disorders. The Company's system, "Referenced-EEG(SM)" or "rEEG(SM)", is the first objective, physiology-based system consistently shown to guide psychiatrists to appropriate treatment in the most challenging patients. It is the culmination of a 20-year effort combining Quantitative Medicine, Psychiatry and Pathology that allows a physician for the first time to determine objectively which CNS (central nervous systems) medications will be effective for a particular patient..

rEEG(SM) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, C
'/>"/>

SOURCE CNS Response, Inc. Copyright©2007 PR Newswire.

0 GOOD

Page: 1 2 3
Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Speaker announces business members of IT Task Force
6. Doyle announces technology tax credits for Berbee
7. Doyle announces new energy, global warming policies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments